Wednesday, May 5, 2021 Daily Archives

Ins & outs: Emergent exec shake up following Bayview 483

by

Emergent announced multiple changes in leadership during its Q1 2021 earnings call to shareholders. Meanwhile, there are changes at Myeloid Therapeutics and Catamaran Bio. Sit back, relax, and enjoy BioProcess Insider’s Ins & Outs. Emergent BioSolutions had been contracted to make millions of doses of Johnson & Johnson and AstraZeneca’s respective vaccines from its Bayview, Maryland plant. However, production was halted at the facility in April after a US Food and Drug Administration (FDA) inspection resulted in a Form 483…

May 5, 2021

SBI hoping to kickstart digital bioprocessing revolution through aquila buy

by

Scientific Bioprocessing (SBI) says it is aiming to create a digital platform to enhance biopharmaceutical workflow through the acquisition of smart sensor and data analytics firm aquila biolabs. Life sciences tool supplier Scientific Industries, through its subsidiary SBI, has acquired aquila biolabs, adding smart sensors and data analytics software for bioprocessing along with facilities in Baesweiler, Germany. “From the earliest interactions with the aquila biolabs team, it became really apparent that we shared the vision of developing technologies that can…

May 5, 2021

Selecta conducts manufacturing review as it takes over MMA program

by

Selecta Biosciences will review a manufacturing issue stemming from a third party after taking over the rights to an methylmalonic acidemia (MMA) gene therapy program. Selecta Biosciences and Asklepios BioPharmaceutical (AskBio – acquired by Bayer in October 2020) entered a joint partnership in August 2019 to advance, produce and commercialize adeno-associated virus (AAV) gene therapies using technology platforms from both firms. While both companies’ will continue their collaboration to assess various gene therapy candidates, after a review of its portfolio…

May 5, 2021